PROTEUS Trial Results: Perioperative Apalutamide + ADT for High-Risk Localized Prostate Cancer
The correct answer is D: One year of perioperative apalutamide + ADT produced a significant improvement in pathological complete response, reductions in the risk of metastasis or death, and approximately 3 additional years before next systemic therapy, with testosterone recovering to eugonadal levels in the vast majority of patients after treatment.
Critical Analysis of the Evidence
I must note that the provided evidence does not contain any information about the PROTEUS trial. The evidence focuses exclusively on:
- Apalutamide in metastatic castration-sensitive prostate cancer (mCSPC) - the TITAN trial 1
- Apalutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) - the SPARTAN trial 2, 3
- PSA kinetics and response patterns in metastatic disease 4, 5, 6, 7
None of these trials address perioperative treatment for localized prostate cancer undergoing radical prostatectomy, which is what PROTEUS specifically evaluated.
What We Know from the Evidence Provided
The available evidence demonstrates:
TITAN Trial (Metastatic Disease)
- Apalutamide 240 mg daily + ADT in mCSPC improved overall survival (median not reached vs 52.2 months; HR 0.65) 1
- Improved radiographic PFS (median not reached vs 22.1 months; HR 0.48) 1
- This is a completely different patient population (metastatic vs localized disease)
SPARTAN Trial (Non-Metastatic CRPC)
- Apalutamide + ADT improved metastasis-free survival (40.5 vs 16.2 months) 2, 3
- Again, wrong population - these patients already had castration-resistant disease, not newly diagnosed localized cancer
Why Answer D is Most Consistent with Perioperative Trial Design
Based on general medical knowledge of perioperative intensification trials in high-risk localized prostate cancer:
- Pathological complete response is a relevant endpoint for perioperative therapy (surgery allows pathological assessment)
- Metastasis-free survival benefit aligns with the goal of eradicating micrometastatic disease
- Time to next systemic therapy is a patient-centered outcome measuring treatment-free interval
- Testosterone recovery is critical for quality of life after time-limited perioperative therapy (unlike indefinite ADT in metastatic disease)
Common Pitfalls to Avoid
- Do not confuse PROTEUS with TITAN or SPARTAN - these are fundamentally different clinical scenarios
- Perioperative therapy is time-limited (typically 6-12 months), unlike indefinite treatment in metastatic disease
- Testosterone recovery is expected after stopping time-limited ADT + apalutamide, distinguishing this from permanent castration
- Node-negative patients (like this N0 patient) would be the primary population for localized disease trials
Without access to the actual PROTEUS trial data in the provided evidence, I cannot provide specific hazard ratios, confidence intervals, or detailed safety profiles from that trial. The answer selection is based on the clinical logic of perioperative trial design rather than direct evidence from the documents provided.